自体细胞因子诱导的杀伤细胞治疗肾癌的临床观察

Clinical observation of autologous cytokine-induced killer cells in the treatment of renal cell carcinoma

摘要:

目的：探讨自体细胞因子诱导的杀伤细胞（cytokine-induced killer cells，CIK）治疗肾癌的临床疗效。方法：将71例肾癌患者随机分入2组，其中治疗组36例，对照组35例，２组患者均先行手术切除，治疗组术后给予白细胞介素（interleukin，IL）-2和干扰素（interferon，IFN）治疗，然后再行CIK细胞回输治疗。对照组术后仅给予IL-2和IFN治疗。观察２组患者的免疫功能、生活质量、生存率及不良反应。结果：治疗组治疗后CD3+、CD4+及CD16+CD56+显著上升，CD8+细胞显著下降，与治疗前比较有明显统计学差异。对照组治疗后CD3+、CD4+、CD4+/CD8+比值及CD16+CD56+及CD8+均无显著变化。治疗组生活质量（quanlity of life，QOL）评分改善83.3%，明显高于对照组的57.1%，２组比较差异有统计学意义。治疗组和对照组的1年生存率分别为91.7%和 80.0%，1年转移率分别为13.9%和22.9%，1年复发率分别为5.6%和11.4%，２组比较差异均无统计学意义。治疗组和对照组的毒副反应比较差异无统计学意义。结论：CIK细胞联合手术治疗肾癌可以提高肾癌患者的免疫功能，改善生活质量。

Abstract:

Objective：To observe the clinical efficacy of autologous cytokine-induced killer cells（CIK） in the treatment of renal carcinoma. Methods：Totally 71 patients with renal carcinoma were randomly divided into treatment group（n=36） and control group（n=35）. Patients in treatment group and control group were received surgical resection first. Then patients in treatment group were treated with interleukin-2 and interferon treatment postoperatively and received CIK cell transfusion therapy at the end of treatment. Patients in control group only received interleukin-2 and interferon treatment. Immune function，quality of life，survival rate and adverse reactions were analyzed. Results：Ratios of CD3+，CD4+ and CD16+CD56+ were increased while those of CD8+ were decreased significantly after the treatment compared with those before the treatment in treatment group. There was no significant change before and after the treatment in ratios of CD3+，CD4+，CD4+/CD8+，CD16+ CD56+ and CD8+ in control group. Quality of life of 83.3% patients in the treatment group was improved while that of 57.1% patients in control group was improved，with statistical differences between two groups. One-year survival rates in treatment group and control group were 91.7% and 80.0%，one-year transfer rates in two groups were 13.9% and 22.9% and one-year recurrence rates in two groups were 5.6% and 11.4 %，respectively，without statistical differences between two groups. There was no statistical difference in side effects between treatment group and control group. Conclusions：CIK cells combined with surgical treatment can improve immune function and quality of life of patients with renal carcinoma.